HDAC inhibitors (e.g., vorinostat and panobinostat) modulate chromatin structure and gene expression by inhibiting histone deacetylases, which can reduce tumor growth and induce apoptosis in glioma cells (Faria et al., 2020). The gene discussed is HDAC9; the disease is central nervous system cancer.